Lymphoma Treatments Market Overview
Lymphoma Treatments Market Size is estimated to reach $13.4 billion by 2027 and it is poised to grow at a CAGR of 8.3% over the forecast period of 2022-2027. Lymphomas belong to the category of blood cancers and thus a substantial proportion of the world population suffers from the following form of cancer. New treatments of lymphoma are supported by the rising R&D expenditure by major pharmaceutical companies that are following aggressive norms to find a long-term cure with alleviated patient comfort. Skin lymphomas can be treated by utilizing steroids, chemotherapy, immunotherapy and various forms of drug inhibitors that control or put the lymphoma into remission. The cost to treat lymphoma varies as per region, however, medical tourism facilities alleviate the traffic to countries such as India, which boost the global lymphoma treatment market. The rising prevalence substantiated by higher diagnostic capacities is the major propeller for Lymphoma Treatments Industry in the forecast period.
Lymphoma Treatments Market Report Coverage
The report: “Lymphoma Treatments Market Forecast (2022-2027)" by IndustryARC, covers an in-depth analysis of the following segments in the Lymphoma Treatments Market.
by Type - Hodgkin and non-Hodgkin Lymphoma.
by Therapy – Immunotherapy, Targeted Therapy, Chemotherapy and Others.
by Distribution Channel - Hospital Pharmacies, Retail Pharmacies & Drug Stores and Online Pharmacies.
by Geography: North America (the U.S., Canada and Mexico), Europe (Germany, United Kingdom (UK), France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of the World (the Middle East and Africa).
- Geographically, North America held a dominant market share in the year 2021 owing to a tremendous diagnostic and cancer treatment market supported by a robust healthcare infrastructure. However, Asia-Pacific is expected to offer lucrative growth opportunities owing to the growing patient pool and geriatric populations.
- The growing cases of lymphomas supported by the alleviating diagnostic and therapeutic segments have presented to be the key market drivers. However, high treatment costs and low insurance coverage impedes the market growth.
- A detailed analysis of the strengths, weaknesses, opportunities and threats will be provided in the Lymphoma Treatments Market Report.
Lymphoma Treatments Market- Market Share (%) by region, 2021.
For More Details on This Report - Request for Sample
Lymphoma Treatments Market Segment Analysis - by Disease Type
Lymphoma Treatments Market based on disease type can be further segmented into Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Non-Hodgkin Lymphoma held a dominant market share in the year 2021. As per NCBI, nearly 77,200 new cases of NHL or Non-Hodgkin lymphoma were diagnosed in 2020 within the U.S., which alleviated the non-Hodgkin lymphoma treatment market. The following form of lymphoma cure rates as per Cancer.Org is nearly 73% on a 5-year survival rate analysis. However, the Hodgkin lymphoma treatment market segment is estimated to be the fastest growing, with a CAGR of 9.8% over the forecast period of 2022-2027. It is owing to various scientific studies highlighting a strong correlation of incidence of the condition with heightened BMI. Owing to a rise in the global obese population, the following segment will provide a higher growth rate.
Lymphoma Treatments Market Segment Analysis - by Distribution Channel
Lymphoma Treatments Market based on distribution channels can be further segmented into hospital pharmacies, retail pharmacies & drug stores and online pharmacies. Hospital Pharmacies held a dominant market share in the year 2021. Moreover, the right dosage with utmost time precision is provided for the patients admitted owing to the conditions. As per the International Federation of Pharmaceuticals, a total number of 113,349 hospital pharmacies can cover nearly 49% of the entire world population. However, online pharmacies is estimated to be the fastest-growing, with a CAGR of 9.4% over the forecast period of 2022-2027. It is owing to a rise in the digital pharmaceutical sector, which proliferates the diagnostic and treatment of lymphoma as a single attribute, at a cheaper cost than other mediums.
Lymphoma Treatments Market Segment Analysis - by Geography
Lymphoma Treatments Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market share of 39% in 2021. It is owing to a higher prevalence of lymphoma, presided by higher disease diagnostic capabilities and treatment awareness with stupendous medical insurance cover. However, Asia-Pacific is expected to offer lucrative growth opportunities in the forecast period of 2022-2027. It is owing to the high growth rate in the approvals for drugs for treating lymphoma-primarily in Japan and South Korea. Moreover, the patient pool is highly subjugated by a growing population, with increasing obesity incidences in regions responsible for the alleviating prevalence of Hodgkin lymphoma. Lymphoma treatment cost in APAC varies as per the country and health insurance policies and coverage norms.
Lymphoma Treatments Market Drivers
The Alleviating Cases of Lymphomas Across the Regions has Fuelled the Marketplace
A critical facet of the growing treatment market for lymphomas is a growing patient pool afflicted with the following. Further, as per analysis from the Frontiers.Org, the age-standardized rate of non-Hodgkin Lymphoma has shown an increasing trend globally from the 1990s to 2019, with an EPAC of 0.56. Meanwhile, increasing trends were observed in both sexes and most geographic regions, particularly in East Asia (EAPC = 3.57, 95% CI: 3.29–3.86). Furthermore, as per a similar source, within India - the projected number of newly diagnosed lymphomas both Hodgkin and Non-Hodgkin stood at nearly 52,000-with NHL leading the share, with estimates suggesting the incidence in 3.3/100,000 of the population.
The Substantial Lymphoma Cure Rates have Driven the Market Growth
As per the American Cancer Society in 2020, an estimated 77,240 individuals underwent diagnostics for NHL. Moreover, the 5-year survival rate for NHL now stands at 73%, which provides optimal opportunities to the patient and healthcare system to provide a cure at the right time. Additionally, a growing initiative in R&D of developing advanced therapies to treat a wide range of lymphomas will help various sub-classes, such as the mantle cell lymphoma treatment market and follicular lymphoma treatment market, amongst others. Profoundly, other forms of lymphomas such as Burkitt’s lymphoma have been considered highly treatable, if diagnosed at earlier stages of malignancies. The growing awareness spread through social media and other digital platforms will help the market growth.
Lymphoma Treatments Market Challenges
Heightened Costs for Utilizing Therapeutics Along with Poor Insurance Coverage Across Various Regions Hampers the Market Growth
The regions of South-East Asia, which have a higher prevalence of lymphoma uniquely have poor insurance coverage, while the treatment costs run high. For example, in Cancer Rounds - the NHL treatment cost for chemotherapy single cycle costs nearly INR 1lakh, while radiation therapy runs close to INR 125,000 a cycle. Although, various government-run organizations are trying to cover treatment costs - however, owing to the longevity of treatment and costs associated with each cycle, a major proportion of costs must be paid out-of-pocket. Although the U.S. and other developed nations have higher insurance coverage but continue to suffer from the high therapy costs.
Lymphoma Treatments Industry Outlook
Product launches, mergers and acqu isitions, joint ventures and geographical expansions are key strategies adopted by players in the Lymphoma Treatments Industry. The top 10 companies in the Lymphoma Treatments market are:
1. Takeda Pharma Company
3. Bayer AG
4. Novartis AG
5. Kite Pharmaceuticals
6. Spectrum Pharmaceuticals
7. Teva Pharmaceuticals
8. Merck and Co.
9. AbbVie Inc.
10. Janssen Pharmaceuticals
- In September 2022, Gilead’s Kite-CAR T Cell Therapy – YESCARTA became the first in Europe to receive a Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma. 41% of the patients demonstrated event-free survival at two years versus 16% who received standard care.
- In September 2022, European Medicines Agency Committee for Medicinal Products for Human Use has gone ahead with providing approval for ZANABRUTINIB in treating marginal zone lymphoma. The following will apply to the patients who have received at least 1 prior anti-CD20-based therapy.
- In June 2021, Novartis announced strong trial data from the analysis of the pivotal phase II ELARA Trial of KYMIRAH, with patients suffering from relapsed or refractory to cure follicular lymphoma.
Report Code- HCR 0191
Report Code- HCR 0124
Report Code- HCR 0178
For more Lifesciences and Healthcare Market reports, please click here